These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

459 related items for PubMed ID: 26614375

  • 1. Role of Somatostatin Analogues in the Treatment of Neuroendocrine Tumors.
    Narayanan S, Kunz PL.
    Hematol Oncol Clin North Am; 2016 Feb; 30(1):163-77. PubMed ID: 26614375
    [Abstract] [Full Text] [Related]

  • 2. Role of somatostatin analogues in the treatment of neuroendocrine tumors.
    Narayanan S, Kunz PL.
    J Natl Compr Canc Netw; 2015 Jan; 13(1):109-17; quiz 117. PubMed ID: 25583773
    [Abstract] [Full Text] [Related]

  • 3. Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future.
    Stueven AK, Kayser A, Wetz C, Amthauer H, Wree A, Tacke F, Wiedenmann B, Roderburg C, Jann H.
    Int J Mol Sci; 2019 Jun 22; 20(12):. PubMed ID: 31234481
    [Abstract] [Full Text] [Related]

  • 4. Systemic Therapies for Advanced Gastrointestinal Carcinoid Tumors.
    Mulvey CK, Bergsland EK.
    Hematol Oncol Clin North Am; 2016 Feb 22; 30(1):63-82. PubMed ID: 26614369
    [Abstract] [Full Text] [Related]

  • 5. Somatostatin analogs in the treatment of neuroendocrine tumors: current and emerging aspects.
    Mazziotti G, Mosca A, Frara S, Vitale G, Giustina A.
    Expert Opin Pharmacother; 2017 Nov 22; 18(16):1679-1689. PubMed ID: 29067877
    [Abstract] [Full Text] [Related]

  • 6. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy.
    Oberg KE, Reubi JC, Kwekkeboom DJ, Krenning EP.
    Gastroenterology; 2010 Sep 22; 139(3):742-53, 753.e1. PubMed ID: 20637207
    [Abstract] [Full Text] [Related]

  • 7. Update on the role of somatostatin analogs for the treatment of patients with gastroenteropancreatic neuroendocrine tumors.
    Toumpanakis C, Caplin ME.
    Semin Oncol; 2013 Feb 22; 40(1):56-68. PubMed ID: 23391113
    [Abstract] [Full Text] [Related]

  • 8. Tumor imaging and therapy using radiolabeled somatostatin analogues.
    de Jong M, Breeman WA, Kwekkeboom DJ, Valkema R, Krenning EP.
    Acc Chem Res; 2009 Jul 21; 42(7):873-80. PubMed ID: 19445476
    [Abstract] [Full Text] [Related]

  • 9. Long-acting somatostatin analogues in the treatment of unresectable/metastatic neuroendocrine tumors.
    Enzler T, Fojo T.
    Semin Oncol; 2017 Apr 21; 44(2):141-156. PubMed ID: 28923213
    [Abstract] [Full Text] [Related]

  • 10. Radioguided surgery and systemic radionuclide therapy of neuroendocrine tumours.
    Hodolic M, Fettich J, Marzola MC, Tonini E, Al-Nahhas A, Rubello D.
    In Vivo; 2010 Apr 21; 24(1):97-100. PubMed ID: 20133983
    [Abstract] [Full Text] [Related]

  • 11. Systemic Therapies for Advanced Pancreatic Neuroendocrine Tumors.
    Raj N, Reidy-Lagunes D.
    Hematol Oncol Clin North Am; 2016 Feb 21; 30(1):119-33. PubMed ID: 26614372
    [Abstract] [Full Text] [Related]

  • 12. [Pharmacologic therapy for neuroendocrine tumours].
    Petrányi A, Bodoky G.
    Orv Hetil; 2011 Mar 06; 152(10):379-91. PubMed ID: 21354954
    [Abstract] [Full Text] [Related]

  • 13. Peptide receptor therapies in neuroendocrine tumors.
    Bodei L, Ferone D, Grana CM, Cremonesi M, Signore A, Dierckx RA, Paganelli G.
    J Endocrinol Invest; 2009 Apr 06; 32(4):360-9. PubMed ID: 19636207
    [Abstract] [Full Text] [Related]

  • 14. New concepts in the treatment strategy of neuroendocrine tumors: the role of biotherapy.
    Papaxoinis G, Syrigos K, Saif MW.
    Discov Med; 2016 May 06; 21(117):381-9. PubMed ID: 27355334
    [Abstract] [Full Text] [Related]

  • 15. Somatostatin analogues in functioning gastroenteropancreatic neuroendocrine tumours: literature review, clinical recommendations and schedules.
    Massironi S, Conte D, Rossi RE.
    Scand J Gastroenterol; 2016 May 06; 51(5):513-23. PubMed ID: 26605828
    [Abstract] [Full Text] [Related]

  • 16. Medical treatment of neuroendocrine tumours.
    Weber HC.
    Curr Opin Endocrinol Diabetes Obes; 2013 Feb 06; 20(1):27-31. PubMed ID: 23221494
    [Abstract] [Full Text] [Related]

  • 17. Lanreotide for the treatment of gastroenteropancreatic neuroendocrine tumors.
    Saif MW.
    Expert Opin Pharmacother; 2016 Feb 06; 17(3):443-56. PubMed ID: 26635177
    [Abstract] [Full Text] [Related]

  • 18. Pasireotide in the treatment of neuroendocrine tumors: a review of the literature.
    Vitale G, Dicitore A, Sciammarella C, Di Molfetta S, Rubino M, Faggiano A, Colao A.
    Endocr Relat Cancer; 2018 Jun 06; 25(6):R351-R364. PubMed ID: 29643113
    [Abstract] [Full Text] [Related]

  • 19. Radiolabeled Somatostatin Analogue Therapy Of Gastroenteropancreatic Cancer.
    Bodei L, Kwekkeboom DJ, Kidd M, Modlin IM, Krenning EP.
    Semin Nucl Med; 2016 May 06; 46(3):225-38. PubMed ID: 27067503
    [Abstract] [Full Text] [Related]

  • 20. Investigational drugs targeting somatostatin receptors for treatment of acromegaly and neuroendocrine tumors.
    Giustina A, Mazziotti G, Maffezzoni F, Amoroso V, Berruti A.
    Expert Opin Investig Drugs; 2014 Dec 06; 23(12):1619-35. PubMed ID: 25060168
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.